Lv12
30 积分 2021-12-02 加入
Cadonilimab is effective and safe in recurrent cervical cancer
1小时前
待确认
Embracing more treatment choices for metastatic, recurrent, or persistent cervical cancer
2小时前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
3小时前
已完结
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
6天前
已完结
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
6天前
已完结
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
30天前
已完结
Survival with Cemiplimab in Recurrent Cervical Cancer
1个月前
已完结
贝伐珠单抗在恶性脑水肿治疗中的应用
1年前
已完结
An Attempt to Stretch the Benefit: Rechallenge with PARP Inhibitors in Ovarian Cancer
1年前
已完结
Anaphylaxis caused by pegylated recombinant human granulocyte colony-stimulating factor
1年前
已完结
皖公网安备34019202002308
